Refine Search

Sanofi, Aventis enter hostile takeover fight

PARIS - Drugmaker Sanofi-Synthelabo SA ended weeks of speculation about a friendly merger with...furthermore "make them shoulder the significant risks to Sanofi-Synthelabo's main products." Aventis has reportedly hired three investment...
Big Movers in the Stock Market

...Market. NYSE Aventis SA, down $5.76 at $74.00 The French drug maker agreed to be bought by its smaller rival Sanofi-Synthelabo for about $63 billion in cash and stock, less than had been expected. Humana Inc., down $1.30 at $17...
New drugs could help smokers break habit

...really have not had enough in their armamentarium to help smokers stop smoking." The French pharmaceutical company Sanofi-Synthelabo said it will ask for FDA approval this year for the drug rimonabant, which it would market under the name Acomplia...
Life & style
Deals seen as welcome sign of recovery's strength

...rival WellPoint Health Networks Inc. for about $14.3 billion in cash and stock. Last month, French drug maker Sanofi-Synthelabo SA unveiled a $60.2 billion hostile bid for larger rival Aventis SA - a combination that would create the world's...
Stocks jump on Greenspan remarks reject a hostile takeover bid by smaller rival Sanofi-Synthelabo. The merger would have created the biggest drug company in the European market. Sanofi-Synthelabo, the maker of anti-stroke drug Plavix and the...
New drug dramatically cuts risks of blood clots after hip replacement

...heparin. The study, reported in Thursday's New England Journal of Medicine, was sponsored by the drug maker Sanofi-Synthelabo, which is seeking approval to sell the yet-unnamed drug in the United States and Europe. Two of the researchers...
XXX Technology